Global Prostate Cancer Diagnostics Market Growth (Status and Outlook) 2026-2032
The global Prostate Cancer Diagnostics market size is predicted to grow from US$ 16321 million in 2025 to US$ 27858 million in 2032; it is expected to grow at a CAGR of 8.1% from 2026 to 2032.
Prostate Cancer Diagnostics refers to a comprehensive set of technologies and products used for the screening, detection, classification, and risk stratification of prostate cancer. It encompasses serum biomarker testing, imaging examinations, molecular diagnostics, biomarker analysis, and histopathological evaluation. Traditional approaches are based on prostate-specific antigen testing, combined with digital rectal examination and biopsy for confirmation. In recent years, multiparametric magnetic resonance imaging, liquid biopsy, gene expression profiling, and multi-parameter algorithmic models have been increasingly adopted, improving early detection and risk stratification accuracy. The core value of prostate cancer diagnostics lies in enabling early screening, reducing overtreatment, supporting personalized therapeutic decisions, and playing a pivotal role in the full-cycle management of oncology care within precision medicine frameworks.The average gross profit margin of this product is 35%.
Accelerating population aging and growing awareness of men?s health provide a solid foundation for expanding prostate cancer screening demand. Healthcare systems are strengthening early cancer screening strategies, broadening coverage across target populations. The advancement of precision medicine has positioned genetic testing and molecular subtyping as major growth drivers. Upgrades in imaging technologies and the integration of artificial intelligence into diagnostic workflows have improved accuracy and efficiency. In addition, the expansion of commercial insurance and premium health check-up markets has enhanced the penetration of high-value diagnostic products. Overall, technological innovation and supportive policies are propelling the industry toward high-quality development.
Prostate-specific antigen testing carries risks of false positives and overdiagnosis, potentially leading to unnecessary biopsies and treatments, thereby increasing healthcare burden and patient anxiety. Variations in screening guidelines across countries affect market expansion dynamics. The high cost of advanced molecular tests and imaging equipment limits penetration in primary healthcare settings. Uncertainties in reimbursement policies and cost-containment pressures may slow commercialization of innovative products. Furthermore, growing concerns over data privacy and genetic information security impose stricter compliance requirements on industry participants.
Downstream demand is concentrated in general hospitals, specialized oncology centers, independent clinical laboratories, and premium health screening institutions. Screening strategies are shifting from single-parameter testing toward multi-marker risk assessment and personalized management. Non-invasive or minimally invasive diagnostic approaches are increasingly favored by patients, expanding the application of liquid biopsy and gene expression testing. The convergence of imaging and molecular diagnostics supports multidisciplinary collaboration models. As chronic disease management concepts deepen, prostate cancer diagnostics are becoming integrated into long-term health management systems.
The upstream segment includes key materials such as antibodies, diagnostic reagents, enzymes, nucleic acid probes, diagnostic chips, and core imaging components. High-quality monoclonal antibodies and standardized calibrators directly influence test sensitivity and specificity. Molecular diagnostics rely on high-purity enzymes, primers, probes, and stable reagent systems. Imaging diagnostics depend on precision electronic components and advanced software algorithms. With the growing emphasis on domestic substitution and supply chain localization, upstream material self-sufficiency has become a critical competitive factor in the industry.
LPI (LP Information)' newest research report, the ?Prostate Cancer Diagnostics Industry Forecast? looks at past sales and reviews total world Prostate Cancer Diagnostics sales in 2025, providing a comprehensive analysis by region and market sector of projected Prostate Cancer Diagnostics sales for 2026 through 2032. With Prostate Cancer Diagnostics sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Prostate Cancer Diagnostics industry.
This Insight Report provides a comprehensive analysis of the global Prostate Cancer Diagnostics landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Prostate Cancer Diagnostics portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Prostate Cancer Diagnostics market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Prostate Cancer Diagnostics and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Prostate Cancer Diagnostics.
This report presents a comprehensive overview, market shares, and growth opportunities of Prostate Cancer Diagnostics market by product type, application, key players and key regions and countries.
Segmentation by Type:
Prostate Cancer Diagnostics refers to a comprehensive set of technologies and products used for the screening, detection, classification, and risk stratification of prostate cancer. It encompasses serum biomarker testing, imaging examinations, molecular diagnostics, biomarker analysis, and histopathological evaluation. Traditional approaches are based on prostate-specific antigen testing, combined with digital rectal examination and biopsy for confirmation. In recent years, multiparametric magnetic resonance imaging, liquid biopsy, gene expression profiling, and multi-parameter algorithmic models have been increasingly adopted, improving early detection and risk stratification accuracy. The core value of prostate cancer diagnostics lies in enabling early screening, reducing overtreatment, supporting personalized therapeutic decisions, and playing a pivotal role in the full-cycle management of oncology care within precision medicine frameworks.The average gross profit margin of this product is 35%.
Accelerating population aging and growing awareness of men?s health provide a solid foundation for expanding prostate cancer screening demand. Healthcare systems are strengthening early cancer screening strategies, broadening coverage across target populations. The advancement of precision medicine has positioned genetic testing and molecular subtyping as major growth drivers. Upgrades in imaging technologies and the integration of artificial intelligence into diagnostic workflows have improved accuracy and efficiency. In addition, the expansion of commercial insurance and premium health check-up markets has enhanced the penetration of high-value diagnostic products. Overall, technological innovation and supportive policies are propelling the industry toward high-quality development.
Prostate-specific antigen testing carries risks of false positives and overdiagnosis, potentially leading to unnecessary biopsies and treatments, thereby increasing healthcare burden and patient anxiety. Variations in screening guidelines across countries affect market expansion dynamics. The high cost of advanced molecular tests and imaging equipment limits penetration in primary healthcare settings. Uncertainties in reimbursement policies and cost-containment pressures may slow commercialization of innovative products. Furthermore, growing concerns over data privacy and genetic information security impose stricter compliance requirements on industry participants.
Downstream demand is concentrated in general hospitals, specialized oncology centers, independent clinical laboratories, and premium health screening institutions. Screening strategies are shifting from single-parameter testing toward multi-marker risk assessment and personalized management. Non-invasive or minimally invasive diagnostic approaches are increasingly favored by patients, expanding the application of liquid biopsy and gene expression testing. The convergence of imaging and molecular diagnostics supports multidisciplinary collaboration models. As chronic disease management concepts deepen, prostate cancer diagnostics are becoming integrated into long-term health management systems.
The upstream segment includes key materials such as antibodies, diagnostic reagents, enzymes, nucleic acid probes, diagnostic chips, and core imaging components. High-quality monoclonal antibodies and standardized calibrators directly influence test sensitivity and specificity. Molecular diagnostics rely on high-purity enzymes, primers, probes, and stable reagent systems. Imaging diagnostics depend on precision electronic components and advanced software algorithms. With the growing emphasis on domestic substitution and supply chain localization, upstream material self-sufficiency has become a critical competitive factor in the industry.
LPI (LP Information)' newest research report, the ?Prostate Cancer Diagnostics Industry Forecast? looks at past sales and reviews total world Prostate Cancer Diagnostics sales in 2025, providing a comprehensive analysis by region and market sector of projected Prostate Cancer Diagnostics sales for 2026 through 2032. With Prostate Cancer Diagnostics sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Prostate Cancer Diagnostics industry.
This Insight Report provides a comprehensive analysis of the global Prostate Cancer Diagnostics landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Prostate Cancer Diagnostics portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Prostate Cancer Diagnostics market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Prostate Cancer Diagnostics and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Prostate Cancer Diagnostics.
This report presents a comprehensive overview, market shares, and growth opportunities of Prostate Cancer Diagnostics market by product type, application, key players and key regions and countries.
Segmentation by Type:
- Tumor Biomarker Tests
- Imaging
- Biopsy
- Other
- Early Screening
- Diagnostic Confirmation
- Risk Stratification
- Therapy Monitoring
- Hospital & Clinic
- Third-party Laboratory
- Other
- Age Below 55
- Age 55-75
- Age Above 75
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- OPKO
- Genomic Health
- Abbott
- Beckman Coulter
- Siemens Healthcare
- bioMeriux
- Roche
- MDx Health
- DiaSorin
- Myriad Genetics
- Ambry Genetics
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Prostate Cancer Diagnostics Market Size (2021-2032)
2.1.2 Prostate Cancer Diagnostics Market Size CAGR by Region (2021 VS 2025 VS 2032)
2.1.3 World Current & Future Analysis for Prostate Cancer Diagnostics by Country/Region (2021, 2025 & 2032)
2.2 Prostate Cancer Diagnostics Segment by Type
2.2.1 Tumor Biomarker Tests
2.2.2 Imaging
2.2.3 Biopsy
2.2.4 Other
2.2.5 Prostate Cancer Diagnostics Market Size by Type
2.2.5.1 Prostate Cancer Diagnostics Market Size CAGR by Type (2021 VS 2025 VS 2032)
2.2.5.2 Global Prostate Cancer Diagnostics Market Size Market Share by Type (2021-2026)
2.3 Prostate Cancer Diagnostics Segment by Clinical Application
2.3.1 Early Screening
2.3.2 Diagnostic Confirmation
2.3.3 Risk Stratification
2.3.4 Therapy Monitoring
2.3.5 Prostate Cancer Diagnostics Market Size by Clinical Application
2.3.5.1 Prostate Cancer Diagnostics Market Size CAGR by Clinical Application (2021 VS 2025 VS 2032)
2.3.5.2 Global Prostate Cancer Diagnostics Market Size Market Share by Clinical Application (2021-2026)
2.4 Prostate Cancer Diagnostics Segment by End Users
2.4.1 Hospital & Clinic
2.4.2 Third-party Laboratory
2.4.3 Other
2.4.4 Prostate Cancer Diagnostics Market Size by End Users
2.4.4.1 Prostate Cancer Diagnostics Market Size CAGR by End Users (2021 VS 2025 VS 2032)
2.4.4.2 Global Prostate Cancer Diagnostics Market Size Market Share by End Users (2021-2026)
2.5 Prostate Cancer Diagnostics Segment by Application
2.5.1 Age Below
2.5.2 Age 55-75
2.5.3 Age Above
2.5.4 Prostate Cancer Diagnostics Market Size by Application
2.5.4.1 Prostate Cancer Diagnostics Market Size CAGR by Application (2021 VS 2025 VS 2032)
2.5.4.2 Global Prostate Cancer Diagnostics Market Size Market Share by Application (2021-2026)
3 PROSTATE CANCER DIAGNOSTICS MARKET SIZE BY PLAYER
3.1 Prostate Cancer Diagnostics Market Size Market Share by Player
3.1.1 Global Prostate Cancer Diagnostics Revenue by Player (2021-2026)
3.1.2 Global Prostate Cancer Diagnostics Revenue Market Share by Player (2021-2026)
3.2 Global Prostate Cancer Diagnostics Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 PROSTATE CANCER DIAGNOSTICS BY REGION
4.1 Prostate Cancer Diagnostics Market Size by Region (2021-2026)
4.2 Global Prostate Cancer Diagnostics Annual Revenue by Country/Region (2021-2026)
4.3 Americas Prostate Cancer Diagnostics Market Size Growth (2021-2026)
4.4 APAC Prostate Cancer Diagnostics Market Size Growth (2021-2026)
4.5 Europe Prostate Cancer Diagnostics Market Size Growth (2021-2026)
4.6 Middle East & Africa Prostate Cancer Diagnostics Market Size Growth (2021-2026)
5 AMERICAS
5.1 Americas Prostate Cancer Diagnostics Market Size by Country (2021-2026)
5.2 Americas Prostate Cancer Diagnostics Market Size by Type (2021-2026)
5.3 Americas Prostate Cancer Diagnostics Market Size by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Prostate Cancer Diagnostics Market Size by Region (2021-2026)
6.2 APAC Prostate Cancer Diagnostics Market Size by Type (2021-2026)
6.3 APAC Prostate Cancer Diagnostics Market Size by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe Prostate Cancer Diagnostics Market Size by Country (2021-2026)
7.2 Europe Prostate Cancer Diagnostics Market Size by Type (2021-2026)
7.3 Europe Prostate Cancer Diagnostics Market Size by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Prostate Cancer Diagnostics by Region (2021-2026)
8.2 Middle East & Africa Prostate Cancer Diagnostics Market Size by Type (2021-2026)
8.3 Middle East & Africa Prostate Cancer Diagnostics Market Size by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET FORECAST
10.1 Global Prostate Cancer Diagnostics Forecast by Region (2027-2032)
10.1.1 Global Prostate Cancer Diagnostics Forecast by Region (2027-2032)
10.1.2 Americas Prostate Cancer Diagnostics Forecast
10.1.3 APAC Prostate Cancer Diagnostics Forecast
10.1.4 Europe Prostate Cancer Diagnostics Forecast
10.1.5 Middle East & Africa Prostate Cancer Diagnostics Forecast
10.2 Americas Prostate Cancer Diagnostics Forecast by Country (2027-2032)
10.2.1 United States Market Prostate Cancer Diagnostics Forecast
10.2.2 Canada Market Prostate Cancer Diagnostics Forecast
10.2.3 Mexico Market Prostate Cancer Diagnostics Forecast
10.2.4 Brazil Market Prostate Cancer Diagnostics Forecast
10.3 APAC Prostate Cancer Diagnostics Forecast by Region (2027-2032)
10.3.1 China Prostate Cancer Diagnostics Market Forecast
10.3.2 Japan Market Prostate Cancer Diagnostics Forecast
10.3.3 Korea Market Prostate Cancer Diagnostics Forecast
10.3.4 Southeast Asia Market Prostate Cancer Diagnostics Forecast
10.3.5 India Market Prostate Cancer Diagnostics Forecast
10.3.6 Australia Market Prostate Cancer Diagnostics Forecast
10.4 Europe Prostate Cancer Diagnostics Forecast by Country (2027-2032)
10.4.1 Germany Market Prostate Cancer Diagnostics Forecast
10.4.2 France Market Prostate Cancer Diagnostics Forecast
10.4.3 UK Market Prostate Cancer Diagnostics Forecast
10.4.4 Italy Market Prostate Cancer Diagnostics Forecast
10.4.5 Russia Market Prostate Cancer Diagnostics Forecast
10.5 Middle East & Africa Prostate Cancer Diagnostics Forecast by Region (2027-2032)
10.5.1 Egypt Market Prostate Cancer Diagnostics Forecast
10.5.2 South Africa Market Prostate Cancer Diagnostics Forecast
10.5.3 Israel Market Prostate Cancer Diagnostics Forecast
10.5.4 Turkey Market Prostate Cancer Diagnostics Forecast
10.6 Global Prostate Cancer Diagnostics Forecast by Type (2027-2032)
10.7 Global Prostate Cancer Diagnostics Forecast by Application (2027-2032)
10.7.1 GCC Countries Market Prostate Cancer Diagnostics Forecast
11 KEY PLAYERS ANALYSIS
11.1 OPKO
11.1.1 OPKO Company Information
11.1.2 OPKO Prostate Cancer Diagnostics Product Offered
11.1.3 OPKO Prostate Cancer Diagnostics Revenue, Gross Margin and Market Share (2021-2026)
11.1.4 OPKO Main Business Overview
11.1.5 OPKO Latest Developments
11.2 Genomic Health
11.2.1 Genomic Health Company Information
11.2.2 Genomic Health Prostate Cancer Diagnostics Product Offered
11.2.3 Genomic Health Prostate Cancer Diagnostics Revenue, Gross Margin and Market Share (2021-2026)
11.2.4 Genomic Health Main Business Overview
11.2.5 Genomic Health Latest Developments
11.3 Abbott
11.3.1 Abbott Company Information
11.3.2 Abbott Prostate Cancer Diagnostics Product Offered
11.3.3 Abbott Prostate Cancer Diagnostics Revenue, Gross Margin and Market Share (2021-2026)
11.3.4 Abbott Main Business Overview
11.3.5 Abbott Latest Developments
11.4 Beckman Coulter
11.4.1 Beckman Coulter Company Information
11.4.2 Beckman Coulter Prostate Cancer Diagnostics Product Offered
11.4.3 Beckman Coulter Prostate Cancer Diagnostics Revenue, Gross Margin and Market Share (2021-2026)
11.4.4 Beckman Coulter Main Business Overview
11.4.5 Beckman Coulter Latest Developments
11.5 Siemens Healthcare
11.5.1 Siemens Healthcare Company Information
11.5.2 Siemens Healthcare Prostate Cancer Diagnostics Product Offered
11.5.3 Siemens Healthcare Prostate Cancer Diagnostics Revenue, Gross Margin and Market Share (2021-2026)
11.5.4 Siemens Healthcare Main Business Overview
11.5.5 Siemens Healthcare Latest Developments
11.6 bioMeriux
11.6.1 bioMeriux Company Information
11.6.2 bioMeriux Prostate Cancer Diagnostics Product Offered
11.6.3 bioMeriux Prostate Cancer Diagnostics Revenue, Gross Margin and Market Share (2021-2026)
11.6.4 bioMeriux Main Business Overview
11.6.5 bioMeriux Latest Developments
11.7 Roche
11.7.1 Roche Company Information
11.7.2 Roche Prostate Cancer Diagnostics Product Offered
11.7.3 Roche Prostate Cancer Diagnostics Revenue, Gross Margin and Market Share (2021-2026)
11.7.4 Roche Main Business Overview
11.7.5 Roche Latest Developments
11.8 MDx Health
11.8.1 MDx Health Company Information
11.8.2 MDx Health Prostate Cancer Diagnostics Product Offered
11.8.3 MDx Health Prostate Cancer Diagnostics Revenue, Gross Margin and Market Share (2021-2026)
11.8.4 MDx Health Main Business Overview
11.8.5 MDx Health Latest Developments
11.9 DiaSorin
11.9.1 DiaSorin Company Information
11.9.2 DiaSorin Prostate Cancer Diagnostics Product Offered
11.9.3 DiaSorin Prostate Cancer Diagnostics Revenue, Gross Margin and Market Share (2021-2026)
11.9.4 DiaSorin Main Business Overview
11.9.5 DiaSorin Latest Developments
11.10 Myriad Genetics
11.10.1 Myriad Genetics Company Information
11.10.2 Myriad Genetics Prostate Cancer Diagnostics Product Offered
11.10.3 Myriad Genetics Prostate Cancer Diagnostics Revenue, Gross Margin and Market Share (2021-2026)
11.10.4 Myriad Genetics Main Business Overview
11.10.5 Myriad Genetics Latest Developments
11.11 Ambry Genetics
11.11.1 Ambry Genetics Company Information
11.11.2 Ambry Genetics Prostate Cancer Diagnostics Product Offered
11.11.3 Ambry Genetics Prostate Cancer Diagnostics Revenue, Gross Margin and Market Share (2021-2026)
11.11.4 Ambry Genetics Main Business Overview
11.11.5 Ambry Genetics Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Prostate Cancer Diagnostics Market Size (2021-2032)
2.1.2 Prostate Cancer Diagnostics Market Size CAGR by Region (2021 VS 2025 VS 2032)
2.1.3 World Current & Future Analysis for Prostate Cancer Diagnostics by Country/Region (2021, 2025 & 2032)
2.2 Prostate Cancer Diagnostics Segment by Type
2.2.1 Tumor Biomarker Tests
2.2.2 Imaging
2.2.3 Biopsy
2.2.4 Other
2.2.5 Prostate Cancer Diagnostics Market Size by Type
2.2.5.1 Prostate Cancer Diagnostics Market Size CAGR by Type (2021 VS 2025 VS 2032)
2.2.5.2 Global Prostate Cancer Diagnostics Market Size Market Share by Type (2021-2026)
2.3 Prostate Cancer Diagnostics Segment by Clinical Application
2.3.1 Early Screening
2.3.2 Diagnostic Confirmation
2.3.3 Risk Stratification
2.3.4 Therapy Monitoring
2.3.5 Prostate Cancer Diagnostics Market Size by Clinical Application
2.3.5.1 Prostate Cancer Diagnostics Market Size CAGR by Clinical Application (2021 VS 2025 VS 2032)
2.3.5.2 Global Prostate Cancer Diagnostics Market Size Market Share by Clinical Application (2021-2026)
2.4 Prostate Cancer Diagnostics Segment by End Users
2.4.1 Hospital & Clinic
2.4.2 Third-party Laboratory
2.4.3 Other
2.4.4 Prostate Cancer Diagnostics Market Size by End Users
2.4.4.1 Prostate Cancer Diagnostics Market Size CAGR by End Users (2021 VS 2025 VS 2032)
2.4.4.2 Global Prostate Cancer Diagnostics Market Size Market Share by End Users (2021-2026)
2.5 Prostate Cancer Diagnostics Segment by Application
2.5.1 Age Below
2.5.2 Age 55-75
2.5.3 Age Above
2.5.4 Prostate Cancer Diagnostics Market Size by Application
2.5.4.1 Prostate Cancer Diagnostics Market Size CAGR by Application (2021 VS 2025 VS 2032)
2.5.4.2 Global Prostate Cancer Diagnostics Market Size Market Share by Application (2021-2026)
3 PROSTATE CANCER DIAGNOSTICS MARKET SIZE BY PLAYER
3.1 Prostate Cancer Diagnostics Market Size Market Share by Player
3.1.1 Global Prostate Cancer Diagnostics Revenue by Player (2021-2026)
3.1.2 Global Prostate Cancer Diagnostics Revenue Market Share by Player (2021-2026)
3.2 Global Prostate Cancer Diagnostics Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 PROSTATE CANCER DIAGNOSTICS BY REGION
4.1 Prostate Cancer Diagnostics Market Size by Region (2021-2026)
4.2 Global Prostate Cancer Diagnostics Annual Revenue by Country/Region (2021-2026)
4.3 Americas Prostate Cancer Diagnostics Market Size Growth (2021-2026)
4.4 APAC Prostate Cancer Diagnostics Market Size Growth (2021-2026)
4.5 Europe Prostate Cancer Diagnostics Market Size Growth (2021-2026)
4.6 Middle East & Africa Prostate Cancer Diagnostics Market Size Growth (2021-2026)
5 AMERICAS
5.1 Americas Prostate Cancer Diagnostics Market Size by Country (2021-2026)
5.2 Americas Prostate Cancer Diagnostics Market Size by Type (2021-2026)
5.3 Americas Prostate Cancer Diagnostics Market Size by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Prostate Cancer Diagnostics Market Size by Region (2021-2026)
6.2 APAC Prostate Cancer Diagnostics Market Size by Type (2021-2026)
6.3 APAC Prostate Cancer Diagnostics Market Size by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe Prostate Cancer Diagnostics Market Size by Country (2021-2026)
7.2 Europe Prostate Cancer Diagnostics Market Size by Type (2021-2026)
7.3 Europe Prostate Cancer Diagnostics Market Size by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Prostate Cancer Diagnostics by Region (2021-2026)
8.2 Middle East & Africa Prostate Cancer Diagnostics Market Size by Type (2021-2026)
8.3 Middle East & Africa Prostate Cancer Diagnostics Market Size by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET FORECAST
10.1 Global Prostate Cancer Diagnostics Forecast by Region (2027-2032)
10.1.1 Global Prostate Cancer Diagnostics Forecast by Region (2027-2032)
10.1.2 Americas Prostate Cancer Diagnostics Forecast
10.1.3 APAC Prostate Cancer Diagnostics Forecast
10.1.4 Europe Prostate Cancer Diagnostics Forecast
10.1.5 Middle East & Africa Prostate Cancer Diagnostics Forecast
10.2 Americas Prostate Cancer Diagnostics Forecast by Country (2027-2032)
10.2.1 United States Market Prostate Cancer Diagnostics Forecast
10.2.2 Canada Market Prostate Cancer Diagnostics Forecast
10.2.3 Mexico Market Prostate Cancer Diagnostics Forecast
10.2.4 Brazil Market Prostate Cancer Diagnostics Forecast
10.3 APAC Prostate Cancer Diagnostics Forecast by Region (2027-2032)
10.3.1 China Prostate Cancer Diagnostics Market Forecast
10.3.2 Japan Market Prostate Cancer Diagnostics Forecast
10.3.3 Korea Market Prostate Cancer Diagnostics Forecast
10.3.4 Southeast Asia Market Prostate Cancer Diagnostics Forecast
10.3.5 India Market Prostate Cancer Diagnostics Forecast
10.3.6 Australia Market Prostate Cancer Diagnostics Forecast
10.4 Europe Prostate Cancer Diagnostics Forecast by Country (2027-2032)
10.4.1 Germany Market Prostate Cancer Diagnostics Forecast
10.4.2 France Market Prostate Cancer Diagnostics Forecast
10.4.3 UK Market Prostate Cancer Diagnostics Forecast
10.4.4 Italy Market Prostate Cancer Diagnostics Forecast
10.4.5 Russia Market Prostate Cancer Diagnostics Forecast
10.5 Middle East & Africa Prostate Cancer Diagnostics Forecast by Region (2027-2032)
10.5.1 Egypt Market Prostate Cancer Diagnostics Forecast
10.5.2 South Africa Market Prostate Cancer Diagnostics Forecast
10.5.3 Israel Market Prostate Cancer Diagnostics Forecast
10.5.4 Turkey Market Prostate Cancer Diagnostics Forecast
10.6 Global Prostate Cancer Diagnostics Forecast by Type (2027-2032)
10.7 Global Prostate Cancer Diagnostics Forecast by Application (2027-2032)
10.7.1 GCC Countries Market Prostate Cancer Diagnostics Forecast
11 KEY PLAYERS ANALYSIS
11.1 OPKO
11.1.1 OPKO Company Information
11.1.2 OPKO Prostate Cancer Diagnostics Product Offered
11.1.3 OPKO Prostate Cancer Diagnostics Revenue, Gross Margin and Market Share (2021-2026)
11.1.4 OPKO Main Business Overview
11.1.5 OPKO Latest Developments
11.2 Genomic Health
11.2.1 Genomic Health Company Information
11.2.2 Genomic Health Prostate Cancer Diagnostics Product Offered
11.2.3 Genomic Health Prostate Cancer Diagnostics Revenue, Gross Margin and Market Share (2021-2026)
11.2.4 Genomic Health Main Business Overview
11.2.5 Genomic Health Latest Developments
11.3 Abbott
11.3.1 Abbott Company Information
11.3.2 Abbott Prostate Cancer Diagnostics Product Offered
11.3.3 Abbott Prostate Cancer Diagnostics Revenue, Gross Margin and Market Share (2021-2026)
11.3.4 Abbott Main Business Overview
11.3.5 Abbott Latest Developments
11.4 Beckman Coulter
11.4.1 Beckman Coulter Company Information
11.4.2 Beckman Coulter Prostate Cancer Diagnostics Product Offered
11.4.3 Beckman Coulter Prostate Cancer Diagnostics Revenue, Gross Margin and Market Share (2021-2026)
11.4.4 Beckman Coulter Main Business Overview
11.4.5 Beckman Coulter Latest Developments
11.5 Siemens Healthcare
11.5.1 Siemens Healthcare Company Information
11.5.2 Siemens Healthcare Prostate Cancer Diagnostics Product Offered
11.5.3 Siemens Healthcare Prostate Cancer Diagnostics Revenue, Gross Margin and Market Share (2021-2026)
11.5.4 Siemens Healthcare Main Business Overview
11.5.5 Siemens Healthcare Latest Developments
11.6 bioMeriux
11.6.1 bioMeriux Company Information
11.6.2 bioMeriux Prostate Cancer Diagnostics Product Offered
11.6.3 bioMeriux Prostate Cancer Diagnostics Revenue, Gross Margin and Market Share (2021-2026)
11.6.4 bioMeriux Main Business Overview
11.6.5 bioMeriux Latest Developments
11.7 Roche
11.7.1 Roche Company Information
11.7.2 Roche Prostate Cancer Diagnostics Product Offered
11.7.3 Roche Prostate Cancer Diagnostics Revenue, Gross Margin and Market Share (2021-2026)
11.7.4 Roche Main Business Overview
11.7.5 Roche Latest Developments
11.8 MDx Health
11.8.1 MDx Health Company Information
11.8.2 MDx Health Prostate Cancer Diagnostics Product Offered
11.8.3 MDx Health Prostate Cancer Diagnostics Revenue, Gross Margin and Market Share (2021-2026)
11.8.4 MDx Health Main Business Overview
11.8.5 MDx Health Latest Developments
11.9 DiaSorin
11.9.1 DiaSorin Company Information
11.9.2 DiaSorin Prostate Cancer Diagnostics Product Offered
11.9.3 DiaSorin Prostate Cancer Diagnostics Revenue, Gross Margin and Market Share (2021-2026)
11.9.4 DiaSorin Main Business Overview
11.9.5 DiaSorin Latest Developments
11.10 Myriad Genetics
11.10.1 Myriad Genetics Company Information
11.10.2 Myriad Genetics Prostate Cancer Diagnostics Product Offered
11.10.3 Myriad Genetics Prostate Cancer Diagnostics Revenue, Gross Margin and Market Share (2021-2026)
11.10.4 Myriad Genetics Main Business Overview
11.10.5 Myriad Genetics Latest Developments
11.11 Ambry Genetics
11.11.1 Ambry Genetics Company Information
11.11.2 Ambry Genetics Prostate Cancer Diagnostics Product Offered
11.11.3 Ambry Genetics Prostate Cancer Diagnostics Revenue, Gross Margin and Market Share (2021-2026)
11.11.4 Ambry Genetics Main Business Overview
11.11.5 Ambry Genetics Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Prostate Cancer Diagnostics Market Size CAGR by Region (2021 VS 2025 VS 2032) & ($ millions)
Table 2. Prostate Cancer Diagnostics Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Tumor Biomarker Tests
Table 4. Major Players of Imaging
Table 5. Major Players of Biopsy
Table 6. Major Players of Other
Table 7. Prostate Cancer Diagnostics Market Size CAGR by Type (2021 VS 2025 VS 2032) & ($ millions)
Table 8. Global Prostate Cancer Diagnostics Market Size by Type (2021-2026) & ($ millions)
Table 9. Global Prostate Cancer Diagnostics Market Size Market Share by Type (2021-2026)
Table 10. Major Players of Early Screening
Table 11. Major Players of Diagnostic Confirmation
Table 12. Major Players of Risk Stratification
Table 13. Major Players of Therapy Monitoring
Table 14. Prostate Cancer Diagnostics Market Size CAGR by Clinical Application (2021 VS 2025 VS 2032) & ($ millions)
Table 15. Global Prostate Cancer Diagnostics Market Size by Clinical Application (2021-2026) & ($ millions)
Table 16. Global Prostate Cancer Diagnostics Market Size Market Share by Clinical Application (2021-2026)
Table 17. Major Players of Hospital & Clinic
Table 18. Major Players of Third-party Laboratory
Table 19. Major Players of Other
Table 20. Prostate Cancer Diagnostics Market Size CAGR by End Users (2021 VS 2025 VS 2032) & ($ millions)
Table 21. Global Prostate Cancer Diagnostics Market Size by End Users (2021-2026) & ($ millions)
Table 22. Global Prostate Cancer Diagnostics Market Size Market Share by End Users (2021-2026)
Table 23. Prostate Cancer Diagnostics Market Size CAGR by Application (2021 VS 2025 VS 2032) & ($ millions)
Table 24. Global Prostate Cancer Diagnostics Market Size by Application (2021-2026) & ($ millions)
Table 25. Global Prostate Cancer Diagnostics Market Size Market Share by Application (2021-2026)
Table 26. Global Prostate Cancer Diagnostics Revenue by Player (2021-2026) & ($ millions)
Table 27. Global Prostate Cancer Diagnostics Revenue Market Share by Player (2021-2026)
Table 28. Prostate Cancer Diagnostics Key Players Head office and Products Offered
Table 29. Prostate Cancer Diagnostics Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 30. New Products and Potential Entrants
Table 31. Mergers & Acquisitions, Expansion
Table 32. Global Prostate Cancer Diagnostics Market Size by Region (2021-2026) & ($ millions)
Table 33. Global Prostate Cancer Diagnostics Market Size Market Share by Region (2021-2026)
Table 34. Global Prostate Cancer Diagnostics Revenue by Country/Region (2021-2026) & ($ millions)
Table 35. Global Prostate Cancer Diagnostics Revenue Market Share by Country/Region (2021-2026)
Table 36. Americas Prostate Cancer Diagnostics Market Size by Country (2021-2026) & ($ millions)
Table 37. Americas Prostate Cancer Diagnostics Market Size Market Share by Country (2021-2026)
Table 38. Americas Prostate Cancer Diagnostics Market Size by Type (2021-2026) & ($ millions)
Table 39. Americas Prostate Cancer Diagnostics Market Size Market Share by Type (2021-2026)
Table 40. Americas Prostate Cancer Diagnostics Market Size by Application (2021-2026) & ($ millions)
Table 41. Americas Prostate Cancer Diagnostics Market Size Market Share by Application (2021-2026)
Table 42. APAC Prostate Cancer Diagnostics Market Size by Region (2021-2026) & ($ millions)
Table 43. APAC Prostate Cancer Diagnostics Market Size Market Share by Region (2021-2026)
Table 44. APAC Prostate Cancer Diagnostics Market Size by Type (2021-2026) & ($ millions)
Table 45. APAC Prostate Cancer Diagnostics Market Size by Application (2021-2026) & ($ millions)
Table 46. Europe Prostate Cancer Diagnostics Market Size by Country (2021-2026) & ($ millions)
Table 47. Europe Prostate Cancer Diagnostics Market Size Market Share by Country (2021-2026)
Table 48. Europe Prostate Cancer Diagnostics Market Size by Type (2021-2026) & ($ millions)
Table 49. Europe Prostate Cancer Diagnostics Market Size by Application (2021-2026) & ($ millions)
Table 50. Middle East & Africa Prostate Cancer Diagnostics Market Size by Region (2021-2026) & ($ millions)
Table 51. Middle East & Africa Prostate Cancer Diagnostics Market Size by Type (2021-2026) & ($ millions)
Table 52. Middle East & Africa Prostate Cancer Diagnostics Market Size by Application (2021-2026) & ($ millions)
Table 53. Key Market Drivers & Growth Opportunities of Prostate Cancer Diagnostics
Table 54. Key Market Challenges & Risks of Prostate Cancer Diagnostics
Table 55. Key Industry Trends of Prostate Cancer Diagnostics
Table 56. Global Prostate Cancer Diagnostics Market Size Forecast by Region (2027-2032) & ($ millions)
Table 57. Global Prostate Cancer Diagnostics Market Size Market Share Forecast by Region (2027-2032)
Table 58. Global Prostate Cancer Diagnostics Market Size Forecast by Type (2027-2032) & ($ millions)
Table 59. Global Prostate Cancer Diagnostics Market Size Forecast by Application (2027-2032) & ($ millions)
Table 60. OPKO Details, Company Type, Prostate Cancer Diagnostics Area Served and Its Competitors
Table 61. OPKO Prostate Cancer Diagnostics Product Offered
Table 62. OPKO Prostate Cancer Diagnostics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 63. OPKO Main Business
Table 64. OPKO Latest Developments
Table 65. Genomic Health Details, Company Type, Prostate Cancer Diagnostics Area Served and Its Competitors
Table 66. Genomic Health Prostate Cancer Diagnostics Product Offered
Table 67. Genomic Health Prostate Cancer Diagnostics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 68. Genomic Health Main Business
Table 69. Genomic Health Latest Developments
Table 70. Abbott Details, Company Type, Prostate Cancer Diagnostics Area Served and Its Competitors
Table 71. Abbott Prostate Cancer Diagnostics Product Offered
Table 72. Abbott Prostate Cancer Diagnostics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 73. Abbott Main Business
Table 74. Abbott Latest Developments
Table 75. Beckman Coulter Details, Company Type, Prostate Cancer Diagnostics Area Served and Its Competitors
Table 76. Beckman Coulter Prostate Cancer Diagnostics Product Offered
Table 77. Beckman Coulter Prostate Cancer Diagnostics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 78. Beckman Coulter Main Business
Table 79. Beckman Coulter Latest Developments
Table 80. Siemens Healthcare Details, Company Type, Prostate Cancer Diagnostics Area Served and Its Competitors
Table 81. Siemens Healthcare Prostate Cancer Diagnostics Product Offered
Table 82. Siemens Healthcare Prostate Cancer Diagnostics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 83. Siemens Healthcare Main Business
Table 84. Siemens Healthcare Latest Developments
Table 85. bioMeriux Details, Company Type, Prostate Cancer Diagnostics Area Served and Its Competitors
Table 86. bioMeriux Prostate Cancer Diagnostics Product Offered
Table 87. bioMeriux Prostate Cancer Diagnostics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 88. bioMeriux Main Business
Table 89. bioMeriux Latest Developments
Table 90. Roche Details, Company Type, Prostate Cancer Diagnostics Area Served and Its Competitors
Table 91. Roche Prostate Cancer Diagnostics Product Offered
Table 92. Roche Prostate Cancer Diagnostics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 93. Roche Main Business
Table 94. Roche Latest Developments
Table 95. MDx Health Details, Company Type, Prostate Cancer Diagnostics Area Served and Its Competitors
Table 96. MDx Health Prostate Cancer Diagnostics Product Offered
Table 97. MDx Health Prostate Cancer Diagnostics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 98. MDx Health Main Business
Table 99. MDx Health Latest Developments
Table 100. DiaSorin Details, Company Type, Prostate Cancer Diagnostics Area Served and Its Competitors
Table 101. DiaSorin Prostate Cancer Diagnostics Product Offered
Table 102. DiaSorin Prostate Cancer Diagnostics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 103. DiaSorin Main Business
Table 104. DiaSorin Latest Developments
Table 105. Myriad Genetics Details, Company Type, Prostate Cancer Diagnostics Area Served and Its Competitors
Table 106. Myriad Genetics Prostate Cancer Diagnostics Product Offered
Table 107. Myriad Genetics Prostate Cancer Diagnostics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 108. Myriad Genetics Main Business
Table 109. Myriad Genetics Latest Developments
Table 110. Ambry Genetics Details, Company Type, Prostate Cancer Diagnostics Area Served and Its Competitors
Table 111. Ambry Genetics Prostate Cancer Diagnostics Product Offered
Table 112. Ambry Genetics Prostate Cancer Diagnostics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 113. Ambry Genetics Main Business
Table 114. Ambry Genetics Latest Developments
Table 1. Prostate Cancer Diagnostics Market Size CAGR by Region (2021 VS 2025 VS 2032) & ($ millions)
Table 2. Prostate Cancer Diagnostics Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Tumor Biomarker Tests
Table 4. Major Players of Imaging
Table 5. Major Players of Biopsy
Table 6. Major Players of Other
Table 7. Prostate Cancer Diagnostics Market Size CAGR by Type (2021 VS 2025 VS 2032) & ($ millions)
Table 8. Global Prostate Cancer Diagnostics Market Size by Type (2021-2026) & ($ millions)
Table 9. Global Prostate Cancer Diagnostics Market Size Market Share by Type (2021-2026)
Table 10. Major Players of Early Screening
Table 11. Major Players of Diagnostic Confirmation
Table 12. Major Players of Risk Stratification
Table 13. Major Players of Therapy Monitoring
Table 14. Prostate Cancer Diagnostics Market Size CAGR by Clinical Application (2021 VS 2025 VS 2032) & ($ millions)
Table 15. Global Prostate Cancer Diagnostics Market Size by Clinical Application (2021-2026) & ($ millions)
Table 16. Global Prostate Cancer Diagnostics Market Size Market Share by Clinical Application (2021-2026)
Table 17. Major Players of Hospital & Clinic
Table 18. Major Players of Third-party Laboratory
Table 19. Major Players of Other
Table 20. Prostate Cancer Diagnostics Market Size CAGR by End Users (2021 VS 2025 VS 2032) & ($ millions)
Table 21. Global Prostate Cancer Diagnostics Market Size by End Users (2021-2026) & ($ millions)
Table 22. Global Prostate Cancer Diagnostics Market Size Market Share by End Users (2021-2026)
Table 23. Prostate Cancer Diagnostics Market Size CAGR by Application (2021 VS 2025 VS 2032) & ($ millions)
Table 24. Global Prostate Cancer Diagnostics Market Size by Application (2021-2026) & ($ millions)
Table 25. Global Prostate Cancer Diagnostics Market Size Market Share by Application (2021-2026)
Table 26. Global Prostate Cancer Diagnostics Revenue by Player (2021-2026) & ($ millions)
Table 27. Global Prostate Cancer Diagnostics Revenue Market Share by Player (2021-2026)
Table 28. Prostate Cancer Diagnostics Key Players Head office and Products Offered
Table 29. Prostate Cancer Diagnostics Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 30. New Products and Potential Entrants
Table 31. Mergers & Acquisitions, Expansion
Table 32. Global Prostate Cancer Diagnostics Market Size by Region (2021-2026) & ($ millions)
Table 33. Global Prostate Cancer Diagnostics Market Size Market Share by Region (2021-2026)
Table 34. Global Prostate Cancer Diagnostics Revenue by Country/Region (2021-2026) & ($ millions)
Table 35. Global Prostate Cancer Diagnostics Revenue Market Share by Country/Region (2021-2026)
Table 36. Americas Prostate Cancer Diagnostics Market Size by Country (2021-2026) & ($ millions)
Table 37. Americas Prostate Cancer Diagnostics Market Size Market Share by Country (2021-2026)
Table 38. Americas Prostate Cancer Diagnostics Market Size by Type (2021-2026) & ($ millions)
Table 39. Americas Prostate Cancer Diagnostics Market Size Market Share by Type (2021-2026)
Table 40. Americas Prostate Cancer Diagnostics Market Size by Application (2021-2026) & ($ millions)
Table 41. Americas Prostate Cancer Diagnostics Market Size Market Share by Application (2021-2026)
Table 42. APAC Prostate Cancer Diagnostics Market Size by Region (2021-2026) & ($ millions)
Table 43. APAC Prostate Cancer Diagnostics Market Size Market Share by Region (2021-2026)
Table 44. APAC Prostate Cancer Diagnostics Market Size by Type (2021-2026) & ($ millions)
Table 45. APAC Prostate Cancer Diagnostics Market Size by Application (2021-2026) & ($ millions)
Table 46. Europe Prostate Cancer Diagnostics Market Size by Country (2021-2026) & ($ millions)
Table 47. Europe Prostate Cancer Diagnostics Market Size Market Share by Country (2021-2026)
Table 48. Europe Prostate Cancer Diagnostics Market Size by Type (2021-2026) & ($ millions)
Table 49. Europe Prostate Cancer Diagnostics Market Size by Application (2021-2026) & ($ millions)
Table 50. Middle East & Africa Prostate Cancer Diagnostics Market Size by Region (2021-2026) & ($ millions)
Table 51. Middle East & Africa Prostate Cancer Diagnostics Market Size by Type (2021-2026) & ($ millions)
Table 52. Middle East & Africa Prostate Cancer Diagnostics Market Size by Application (2021-2026) & ($ millions)
Table 53. Key Market Drivers & Growth Opportunities of Prostate Cancer Diagnostics
Table 54. Key Market Challenges & Risks of Prostate Cancer Diagnostics
Table 55. Key Industry Trends of Prostate Cancer Diagnostics
Table 56. Global Prostate Cancer Diagnostics Market Size Forecast by Region (2027-2032) & ($ millions)
Table 57. Global Prostate Cancer Diagnostics Market Size Market Share Forecast by Region (2027-2032)
Table 58. Global Prostate Cancer Diagnostics Market Size Forecast by Type (2027-2032) & ($ millions)
Table 59. Global Prostate Cancer Diagnostics Market Size Forecast by Application (2027-2032) & ($ millions)
Table 60. OPKO Details, Company Type, Prostate Cancer Diagnostics Area Served and Its Competitors
Table 61. OPKO Prostate Cancer Diagnostics Product Offered
Table 62. OPKO Prostate Cancer Diagnostics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 63. OPKO Main Business
Table 64. OPKO Latest Developments
Table 65. Genomic Health Details, Company Type, Prostate Cancer Diagnostics Area Served and Its Competitors
Table 66. Genomic Health Prostate Cancer Diagnostics Product Offered
Table 67. Genomic Health Prostate Cancer Diagnostics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 68. Genomic Health Main Business
Table 69. Genomic Health Latest Developments
Table 70. Abbott Details, Company Type, Prostate Cancer Diagnostics Area Served and Its Competitors
Table 71. Abbott Prostate Cancer Diagnostics Product Offered
Table 72. Abbott Prostate Cancer Diagnostics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 73. Abbott Main Business
Table 74. Abbott Latest Developments
Table 75. Beckman Coulter Details, Company Type, Prostate Cancer Diagnostics Area Served and Its Competitors
Table 76. Beckman Coulter Prostate Cancer Diagnostics Product Offered
Table 77. Beckman Coulter Prostate Cancer Diagnostics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 78. Beckman Coulter Main Business
Table 79. Beckman Coulter Latest Developments
Table 80. Siemens Healthcare Details, Company Type, Prostate Cancer Diagnostics Area Served and Its Competitors
Table 81. Siemens Healthcare Prostate Cancer Diagnostics Product Offered
Table 82. Siemens Healthcare Prostate Cancer Diagnostics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 83. Siemens Healthcare Main Business
Table 84. Siemens Healthcare Latest Developments
Table 85. bioMeriux Details, Company Type, Prostate Cancer Diagnostics Area Served and Its Competitors
Table 86. bioMeriux Prostate Cancer Diagnostics Product Offered
Table 87. bioMeriux Prostate Cancer Diagnostics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 88. bioMeriux Main Business
Table 89. bioMeriux Latest Developments
Table 90. Roche Details, Company Type, Prostate Cancer Diagnostics Area Served and Its Competitors
Table 91. Roche Prostate Cancer Diagnostics Product Offered
Table 92. Roche Prostate Cancer Diagnostics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 93. Roche Main Business
Table 94. Roche Latest Developments
Table 95. MDx Health Details, Company Type, Prostate Cancer Diagnostics Area Served and Its Competitors
Table 96. MDx Health Prostate Cancer Diagnostics Product Offered
Table 97. MDx Health Prostate Cancer Diagnostics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 98. MDx Health Main Business
Table 99. MDx Health Latest Developments
Table 100. DiaSorin Details, Company Type, Prostate Cancer Diagnostics Area Served and Its Competitors
Table 101. DiaSorin Prostate Cancer Diagnostics Product Offered
Table 102. DiaSorin Prostate Cancer Diagnostics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 103. DiaSorin Main Business
Table 104. DiaSorin Latest Developments
Table 105. Myriad Genetics Details, Company Type, Prostate Cancer Diagnostics Area Served and Its Competitors
Table 106. Myriad Genetics Prostate Cancer Diagnostics Product Offered
Table 107. Myriad Genetics Prostate Cancer Diagnostics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 108. Myriad Genetics Main Business
Table 109. Myriad Genetics Latest Developments
Table 110. Ambry Genetics Details, Company Type, Prostate Cancer Diagnostics Area Served and Its Competitors
Table 111. Ambry Genetics Prostate Cancer Diagnostics Product Offered
Table 112. Ambry Genetics Prostate Cancer Diagnostics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 113. Ambry Genetics Main Business
Table 114. Ambry Genetics Latest Developments
LIST OF FIGURES
Figure 1. Prostate Cancer Diagnostics Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Prostate Cancer Diagnostics Market Size Growth Rate (2021-2032) ($ millions)
Figure 6. Prostate Cancer Diagnostics Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 7. Prostate Cancer Diagnostics Sales Market Share by Country/Region (2025)
Figure 8. Prostate Cancer Diagnostics Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 9. Global Prostate Cancer Diagnostics Market Size Market Share by Type in 2025
Figure 10. Global Prostate Cancer Diagnostics Market Size Market Share by Clinical Application in 2025
Figure 11. Global Prostate Cancer Diagnostics Market Size Market Share by End Users in 2025
Figure 12. Prostate Cancer Diagnostics in Age Below 55
Figure 13. Global Prostate Cancer Diagnostics Market: Age Below 55 (2021-2026) & ($ millions)
Figure 14. Prostate Cancer Diagnostics in Age 55-75
Figure 15. Global Prostate Cancer Diagnostics Market: Age 55-75 (2021-2026) & ($ millions)
Figure 16. Prostate Cancer Diagnostics in Age Above 75
Figure 17. Global Prostate Cancer Diagnostics Market: Age Above 75 (2021-2026) & ($ millions)
Figure 18. Global Prostate Cancer Diagnostics Market Size Market Share by Application in 2025
Figure 19. Global Prostate Cancer Diagnostics Revenue Market Share by Player in 2025
Figure 20. Global Prostate Cancer Diagnostics Market Size Market Share by Region (2021-2026)
Figure 21. Americas Prostate Cancer Diagnostics Market Size 2021-2026 ($ millions)
Figure 22. APAC Prostate Cancer Diagnostics Market Size 2021-2026 ($ millions)
Figure 23. Europe Prostate Cancer Diagnostics Market Size 2021-2026 ($ millions)
Figure 24. Middle East & Africa Prostate Cancer Diagnostics Market Size 2021-2026 ($ millions)
Figure 25. Americas Prostate Cancer Diagnostics Value Market Share by Country in 2025
Figure 26. United States Prostate Cancer Diagnostics Market Size Growth 2021-2026 ($ millions)
Figure 27. Canada Prostate Cancer Diagnostics Market Size Growth 2021-2026 ($ millions)
Figure 28. Mexico Prostate Cancer Diagnostics Market Size Growth 2021-2026 ($ millions)
Figure 29. Brazil Prostate Cancer Diagnostics Market Size Growth 2021-2026 ($ millions)
Figure 30. APAC Prostate Cancer Diagnostics Market Size Market Share by Region in 2025
Figure 31. APAC Prostate Cancer Diagnostics Market Size Market Share by Type (2021-2026)
Figure 32. APAC Prostate Cancer Diagnostics Market Size Market Share by Application (2021-2026)
Figure 33. China Prostate Cancer Diagnostics Market Size Growth 2021-2026 ($ millions)
Figure 34. Japan Prostate Cancer Diagnostics Market Size Growth 2021-2026 ($ millions)
Figure 35. South Korea Prostate Cancer Diagnostics Market Size Growth 2021-2026 ($ millions)
Figure 36. Southeast Asia Prostate Cancer Diagnostics Market Size Growth 2021-2026 ($ millions)
Figure 37. India Prostate Cancer Diagnostics Market Size Growth 2021-2026 ($ millions)
Figure 38. Australia Prostate Cancer Diagnostics Market Size Growth 2021-2026 ($ millions)
Figure 39. Europe Prostate Cancer Diagnostics Market Size Market Share by Country in 2025
Figure 40. Europe Prostate Cancer Diagnostics Market Size Market Share by Type (2021-2026)
Figure 41. Europe Prostate Cancer Diagnostics Market Size Market Share by Application (2021-2026)
Figure 42. Germany Prostate Cancer Diagnostics Market Size Growth 2021-2026 ($ millions)
Figure 43. France Prostate Cancer Diagnostics Market Size Growth 2021-2026 ($ millions)
Figure 44. UK Prostate Cancer Diagnostics Market Size Growth 2021-2026 ($ millions)
Figure 45. Italy Prostate Cancer Diagnostics Market Size Growth 2021-2026 ($ millions)
Figure 46. Russia Prostate Cancer Diagnostics Market Size Growth 2021-2026 ($ millions)
Figure 47. Middle East & Africa Prostate Cancer Diagnostics Market Size Market Share by Region (2021-2026)
Figure 48. Middle East & Africa Prostate Cancer Diagnostics Market Size Market Share by Type (2021-2026)
Figure 49. Middle East & Africa Prostate Cancer Diagnostics Market Size Market Share by Application (2021-2026)
Figure 50. Egypt Prostate Cancer Diagnostics Market Size Growth 2021-2026 ($ millions)
Figure 51. South Africa Prostate Cancer Diagnostics Market Size Growth 2021-2026 ($ millions)
Figure 52. Israel Prostate Cancer Diagnostics Market Size Growth 2021-2026 ($ millions)
Figure 53. Turkey Prostate Cancer Diagnostics Market Size Growth 2021-2026 ($ millions)
Figure 54. GCC Countries Prostate Cancer Diagnostics Market Size Growth 2021-2026 ($ millions)
Figure 55. Americas Prostate Cancer Diagnostics Market Size 2027-2032 ($ millions)
Figure 56. APAC Prostate Cancer Diagnostics Market Size 2027-2032 ($ millions)
Figure 57. Europe Prostate Cancer Diagnostics Market Size 2027-2032 ($ millions)
Figure 58. Middle East & Africa Prostate Cancer Diagnostics Market Size 2027-2032 ($ millions)
Figure 59. United States Prostate Cancer Diagnostics Market Size 2027-2032 ($ millions)
Figure 60. Canada Prostate Cancer Diagnostics Market Size 2027-2032 ($ millions)
Figure 61. Mexico Prostate Cancer Diagnostics Market Size 2027-2032 ($ millions)
Figure 62. Brazil Prostate Cancer Diagnostics Market Size 2027-2032 ($ millions)
Figure 63. China Prostate Cancer Diagnostics Market Size 2027-2032 ($ millions)
Figure 64. Japan Prostate Cancer Diagnostics Market Size 2027-2032 ($ millions)
Figure 65. Korea Prostate Cancer Diagnostics Market Size 2027-2032 ($ millions)
Figure 66. Southeast Asia Prostate Cancer Diagnostics Market Size 2027-2032 ($ millions)
Figure 67. India Prostate Cancer Diagnostics Market Size 2027-2032 ($ millions)
Figure 68. Australia Prostate Cancer Diagnostics Market Size 2027-2032 ($ millions)
Figure 69. Germany Prostate Cancer Diagnostics Market Size 2027-2032 ($ millions)
Figure 70. France Prostate Cancer Diagnostics Market Size 2027-2032 ($ millions)
Figure 71. UK Prostate Cancer Diagnostics Market Size 2027-2032 ($ millions)
Figure 72. Italy Prostate Cancer Diagnostics Market Size 2027-2032 ($ millions)
Figure 73. Russia Prostate Cancer Diagnostics Market Size 2027-2032 ($ millions)
Figure 74. Egypt Prostate Cancer Diagnostics Market Size 2027-2032 ($ millions)
Figure 75. South Africa Prostate Cancer Diagnostics Market Size 2027-2032 ($ millions)
Figure 76. Israel Prostate Cancer Diagnostics Market Size 2027-2032 ($ millions)
Figure 77. Turkey Prostate Cancer Diagnostics Market Size 2027-2032 ($ millions)
Figure 78. Global Prostate Cancer Diagnostics Market Size Market Share Forecast by Type (2027-2032)
Figure 79. Global Prostate Cancer Diagnostics Market Size Market Share Forecast by Application (2027-2032)
Figure 80. GCC Countries Prostate Cancer Diagnostics Market Size 2027-2032 ($ millions)
Figure 1. Prostate Cancer Diagnostics Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Prostate Cancer Diagnostics Market Size Growth Rate (2021-2032) ($ millions)
Figure 6. Prostate Cancer Diagnostics Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 7. Prostate Cancer Diagnostics Sales Market Share by Country/Region (2025)
Figure 8. Prostate Cancer Diagnostics Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 9. Global Prostate Cancer Diagnostics Market Size Market Share by Type in 2025
Figure 10. Global Prostate Cancer Diagnostics Market Size Market Share by Clinical Application in 2025
Figure 11. Global Prostate Cancer Diagnostics Market Size Market Share by End Users in 2025
Figure 12. Prostate Cancer Diagnostics in Age Below 55
Figure 13. Global Prostate Cancer Diagnostics Market: Age Below 55 (2021-2026) & ($ millions)
Figure 14. Prostate Cancer Diagnostics in Age 55-75
Figure 15. Global Prostate Cancer Diagnostics Market: Age 55-75 (2021-2026) & ($ millions)
Figure 16. Prostate Cancer Diagnostics in Age Above 75
Figure 17. Global Prostate Cancer Diagnostics Market: Age Above 75 (2021-2026) & ($ millions)
Figure 18. Global Prostate Cancer Diagnostics Market Size Market Share by Application in 2025
Figure 19. Global Prostate Cancer Diagnostics Revenue Market Share by Player in 2025
Figure 20. Global Prostate Cancer Diagnostics Market Size Market Share by Region (2021-2026)
Figure 21. Americas Prostate Cancer Diagnostics Market Size 2021-2026 ($ millions)
Figure 22. APAC Prostate Cancer Diagnostics Market Size 2021-2026 ($ millions)
Figure 23. Europe Prostate Cancer Diagnostics Market Size 2021-2026 ($ millions)
Figure 24. Middle East & Africa Prostate Cancer Diagnostics Market Size 2021-2026 ($ millions)
Figure 25. Americas Prostate Cancer Diagnostics Value Market Share by Country in 2025
Figure 26. United States Prostate Cancer Diagnostics Market Size Growth 2021-2026 ($ millions)
Figure 27. Canada Prostate Cancer Diagnostics Market Size Growth 2021-2026 ($ millions)
Figure 28. Mexico Prostate Cancer Diagnostics Market Size Growth 2021-2026 ($ millions)
Figure 29. Brazil Prostate Cancer Diagnostics Market Size Growth 2021-2026 ($ millions)
Figure 30. APAC Prostate Cancer Diagnostics Market Size Market Share by Region in 2025
Figure 31. APAC Prostate Cancer Diagnostics Market Size Market Share by Type (2021-2026)
Figure 32. APAC Prostate Cancer Diagnostics Market Size Market Share by Application (2021-2026)
Figure 33. China Prostate Cancer Diagnostics Market Size Growth 2021-2026 ($ millions)
Figure 34. Japan Prostate Cancer Diagnostics Market Size Growth 2021-2026 ($ millions)
Figure 35. South Korea Prostate Cancer Diagnostics Market Size Growth 2021-2026 ($ millions)
Figure 36. Southeast Asia Prostate Cancer Diagnostics Market Size Growth 2021-2026 ($ millions)
Figure 37. India Prostate Cancer Diagnostics Market Size Growth 2021-2026 ($ millions)
Figure 38. Australia Prostate Cancer Diagnostics Market Size Growth 2021-2026 ($ millions)
Figure 39. Europe Prostate Cancer Diagnostics Market Size Market Share by Country in 2025
Figure 40. Europe Prostate Cancer Diagnostics Market Size Market Share by Type (2021-2026)
Figure 41. Europe Prostate Cancer Diagnostics Market Size Market Share by Application (2021-2026)
Figure 42. Germany Prostate Cancer Diagnostics Market Size Growth 2021-2026 ($ millions)
Figure 43. France Prostate Cancer Diagnostics Market Size Growth 2021-2026 ($ millions)
Figure 44. UK Prostate Cancer Diagnostics Market Size Growth 2021-2026 ($ millions)
Figure 45. Italy Prostate Cancer Diagnostics Market Size Growth 2021-2026 ($ millions)
Figure 46. Russia Prostate Cancer Diagnostics Market Size Growth 2021-2026 ($ millions)
Figure 47. Middle East & Africa Prostate Cancer Diagnostics Market Size Market Share by Region (2021-2026)
Figure 48. Middle East & Africa Prostate Cancer Diagnostics Market Size Market Share by Type (2021-2026)
Figure 49. Middle East & Africa Prostate Cancer Diagnostics Market Size Market Share by Application (2021-2026)
Figure 50. Egypt Prostate Cancer Diagnostics Market Size Growth 2021-2026 ($ millions)
Figure 51. South Africa Prostate Cancer Diagnostics Market Size Growth 2021-2026 ($ millions)
Figure 52. Israel Prostate Cancer Diagnostics Market Size Growth 2021-2026 ($ millions)
Figure 53. Turkey Prostate Cancer Diagnostics Market Size Growth 2021-2026 ($ millions)
Figure 54. GCC Countries Prostate Cancer Diagnostics Market Size Growth 2021-2026 ($ millions)
Figure 55. Americas Prostate Cancer Diagnostics Market Size 2027-2032 ($ millions)
Figure 56. APAC Prostate Cancer Diagnostics Market Size 2027-2032 ($ millions)
Figure 57. Europe Prostate Cancer Diagnostics Market Size 2027-2032 ($ millions)
Figure 58. Middle East & Africa Prostate Cancer Diagnostics Market Size 2027-2032 ($ millions)
Figure 59. United States Prostate Cancer Diagnostics Market Size 2027-2032 ($ millions)
Figure 60. Canada Prostate Cancer Diagnostics Market Size 2027-2032 ($ millions)
Figure 61. Mexico Prostate Cancer Diagnostics Market Size 2027-2032 ($ millions)
Figure 62. Brazil Prostate Cancer Diagnostics Market Size 2027-2032 ($ millions)
Figure 63. China Prostate Cancer Diagnostics Market Size 2027-2032 ($ millions)
Figure 64. Japan Prostate Cancer Diagnostics Market Size 2027-2032 ($ millions)
Figure 65. Korea Prostate Cancer Diagnostics Market Size 2027-2032 ($ millions)
Figure 66. Southeast Asia Prostate Cancer Diagnostics Market Size 2027-2032 ($ millions)
Figure 67. India Prostate Cancer Diagnostics Market Size 2027-2032 ($ millions)
Figure 68. Australia Prostate Cancer Diagnostics Market Size 2027-2032 ($ millions)
Figure 69. Germany Prostate Cancer Diagnostics Market Size 2027-2032 ($ millions)
Figure 70. France Prostate Cancer Diagnostics Market Size 2027-2032 ($ millions)
Figure 71. UK Prostate Cancer Diagnostics Market Size 2027-2032 ($ millions)
Figure 72. Italy Prostate Cancer Diagnostics Market Size 2027-2032 ($ millions)
Figure 73. Russia Prostate Cancer Diagnostics Market Size 2027-2032 ($ millions)
Figure 74. Egypt Prostate Cancer Diagnostics Market Size 2027-2032 ($ millions)
Figure 75. South Africa Prostate Cancer Diagnostics Market Size 2027-2032 ($ millions)
Figure 76. Israel Prostate Cancer Diagnostics Market Size 2027-2032 ($ millions)
Figure 77. Turkey Prostate Cancer Diagnostics Market Size 2027-2032 ($ millions)
Figure 78. Global Prostate Cancer Diagnostics Market Size Market Share Forecast by Type (2027-2032)
Figure 79. Global Prostate Cancer Diagnostics Market Size Market Share Forecast by Application (2027-2032)
Figure 80. GCC Countries Prostate Cancer Diagnostics Market Size 2027-2032 ($ millions)
